Login to Your Account

China advances efforts to streamline drug marketing authorization process

By Cornelia Zou
Staff Writer

Wednesday, August 23, 2017

HONG KONG – China's drug authority is upscaling the Marketing Authorization Holder (MAH) mechanism pilot, which is seen as a boon for drug innovation in the country.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription